Metabolic profiling based on nuclear magnetic resonance spectroscopy and mass spectrometry as a tool for clinical application

Metabolomics provides an abundance of information with the potential to accurately describe the physiological state of an organism. It aims to identify small molecules under physiological conditions that might serve as biomarkers and aid in the identification and treatment of health problems. Combin...

Full description

Saved in:
Bibliographic Details
Published inUrological science Vol. 30; no. 4; pp. 144 - 150
Main Authors Garcia-Perdomo, Herney, Vallejo, Felipe, Sanchez, Adalberto
Format Journal Article
LanguageEnglish
Published Wolters Kluwer India Pvt. Ltd 01.07.2019
Medknow Publications and Media Pvt. Ltd
Subjects
Amino acids
Biological markers
Criminal investigation
Health
Mass spectrometry
Nuclear magnetic resonance spectroscopy
Physiological aspects
Spectroscopy
nuclear magnetic resonance spectroscopy
urologic oncology
mass spectrometry
metabolic profile
Cancer
Online AccessGet full text

Cover

More Information
Summary:Metabolomics provides an abundance of information with the potential to accurately describe the physiological state of an organism. It aims to identify small molecules under physiological conditions that might serve as biomarkers and aid in the identification and treatment of health problems. Combining nuclear magnetic resonance (NMR) with mass spectrometry (MS) yields better identification and quantification of compounds, especially in mixtures, as well as the ability to cross-analyze data from both techniques and thereby increase the number of compounds identified. Metabolomic profiling using NMR and/or MS provides an important diagnostic tool for identifying metabolites under different conditions. This also requires a valid and reliable way to standardize the way we use it to identify biomarkers. Regarding the clinical application of metabolomics, for bladder cancer, threonine, phenylalanine, valine, isoleucine, lysine, methionine, leucine, glutamate, histidine, arginine, aspartic acid, tyrosine, glutamine, and serine were found discriminative in diagnosing this entity. On the other side, sarcosine, choline, phosphocholines, phosphorylcholines, carnitines, citrate, amino acids (lysine, glutamine, and ornithine), arachidonoyl amine, and lysophospholipids were found discriminative regarding the prostate cancer diagnosis.
ISSN:1879-5226
1879-5234
DOI:10.4103/UROS.UROS_2_19